Home » Health Policy » Pharmaceutical Policy and Regulation

Category Archives: Pharmaceutical Policy and Regulation

How Health Care Providers Can Help End the Overprescription of Opioids

Battling the opioid epidemic requires flexible, carefully designed, and rapidly evaluated policies.  (more…)

Switch and Save on Medicare Part D

Simply switching prescription drug plans could save seniors and the government billions. (more…)

A Billion Here, a Billion There: Selectively Disclosing Actual Generic Drug Prices Would Save Real Money

Opportunities exist to lower spending on generic drugs—and reduce total health care spending.

(more…)

Reining In Pharmaceutical Costs

The administration and lawmakers should prioritize four actions that could engender more cooperation and improve health over the long-term. (more…)

Follow The Money: The Flow Of Funds In The Pharmaceutical Distribution System

Any government intervention to control drug pricing should be predicated on a clear understanding of the economic forces that drive price increases, and the parties responsible for them. (more…)

Value-based drug pricing makes sense, but is difficult to pull off

Dana Goldman and Anupam Jena discuss the challenges of value-based pricing and health technology assessments. (more…)

Value-Based Pricing For Pharmaceuticals In The Trump Administration

The change in administration is an opportune moment for CMS to assume a leadership role with respect to value-based pricing.  (more…)

A Good Deal For Eliminating Hepatitis C: Saving Money And Lives

Hepatitis C kills more than 20,000 Americans each year. A recent consensus committee of the National Academies of Sciences, Engineering, and Medicine proposed a novel strategy to improve access to hepatitis C medicines. (more…)

How Expanding the Role of Pharmacists Lowered Readmissions and Costs in one California Community

Technology and data can help pharmacists provide services required to manage life-long, outpatient drug therapies. (more…)

Sky-High Drug Prices for Rare Diseases Show Why Orphan Drug Act Needs Reform

The Orphan Drug Act (ODA) was passed 34 years ago to promote development of drugs aimed at diseases that afflict small groups, typically under 200,000 people. However, the nature of drug development has changed. Our researchers see an opportunity for improvement. (more…)

Follow CESR on Facebook



Follow Schaeffer on Facebook